Kletzmayr A Mulay SR Motrapu M Luo Z Anders HJ Ivarsson ME Leroux JC 2020 Calcium oxalate (CaOx) crystal-induced nephropathies comprise a range of kidney disorders, for which there are no efficient pharmacological treatments. Although CaOx crystallization inhibitors have been suggested as a therapeutic modality already decades ago, limited progress has been made in the discovery of potent molecules with efficacy in animal disease models. Herein, an image-based machine learning approach to systematically screen chemically modified myo-inositol hexakisphosphate (IP6) analogues is utilized, which enables the identification of a highly active divalent inositol phosphate molecule. To date, this is the first molecule shown to completely inhibit the crystallization process in the nanomolar range, reduce crystal-cell interactions, thereby preventing CaOx-induced transcriptomic changes, and decrease renal CaOx deposition and kidney injury in a mouse model of hyperoxaluria. In conclusion, IP6 analogues based on such a scaffold may represent a new treatment option for CaOx nephropathies. application/pdf https://sonar.ch/global/documents/244274 eng info:eu-repo/semantics/altIdentifier/doi/10.1002/advs.201903337 info:eu-repo/semantics/altIdentifier/pmid/32328427 info:eu-repo/semantics/openAccess Advanced science (Weinheim, Baden-Wurttemberg, Germany). - 2020 calcium oxalate crystallization inhibitors chronic kidney disease image‐based drug screening kidney calcification kidney stones Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies. http://purl.org/coar/resource_type/c_6501